Your session is about to expire
← Back to Search
[89Zr]Panitumumab PET-MRI for Colon Cancer (Panitumumab Trial)
Phase 1 & 2
Waitlist Available
Led By Suzanne Lapi, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Panitumumab Trial Summary
This trial will use PET imaging with [89Zr]Panitumumab to assess if and how much EGFR expression is present in colon cancer patients' lymph nodes to help determine if they are involved in the cancer.
Eligible Conditions
- Colon Cancer
Panitumumab Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Image Quality
Panitumumab Trial Design
1Treatment groups
Experimental Treatment
Group I: [89Zr]Panitumumab-PET/MRI patientsExperimental Treatment1 Intervention
All study patients will receive [89Zr]Panitumumab-PET/MRI imaging.
Find a Location
Who is running the clinical trial?
University of Alabama at BirminghamLead Sponsor
1,590 Previous Clinical Trials
2,281,482 Total Patients Enrolled
Suzanne Lapi, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
1 Previous Clinical Trials
14 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger